CRISPR Screens Identify Essential Cell Growth Mediators in BRAF-inhibitor Resistant Melanoma

BRAF is a serine-threonine kinase that harbors activating mutations in ∼7% of human malignancies and ∼60% of melanomas. Despite initial clinical responses to BRAF inhibitors (BRAFi), patients frequently develop drug resistance. To identify candidate therapeutic targets for BRAFi-resistant melanoma, we conducted CRISPR screens in melanoma cells harboring an activating BRAF mutation that had also acquired resistance to BRAFi. The screens identified pathways and genes critical for BRAFi resistance in melanoma cells. To investigate the mechanisms and pathways enabling resistance to BRAFi in melanomas, we integrated expression data, ATAC-seq, and CRISPR screen results. We identified the JUN family of transcription factors and the ETS family transcription factor ETV5 as key regulators of CDK6 that enabled resistance to BRAFi in melanoma cells. Our findings reveal genes whose loss of function conferred resistance to a selective BRAF inhibitor, providing new insight into signaling pathways that contribute to acquired resistance in melanoma.

[1]  W. Wiedemeyer,et al.  Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS , 2014, Oncotarget.

[2]  L. Chin,et al.  Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. , 2015, The Journal of clinical investigation.

[3]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[4]  A. Hauschild,et al.  Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. , 2014, The Lancet. Oncology.

[5]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[6]  John G Doench,et al.  ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. , 2017, Cell reports.

[7]  C. Peyssonnaux,et al.  The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.

[8]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[9]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Barbacid,et al.  To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.

[11]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[12]  Mauro A. A. Castro,et al.  The chromatin accessibility landscape of primary human cancers , 2018, Science.

[13]  M. Barbacid,et al.  Is Cyclin D1-CDK4 kinase a bona fide cancer target? , 2006, Cancer cell.

[14]  Alex H. Wagner,et al.  DGIdb 3.0: a redesign and expansion of the drug–gene interaction database , 2017, bioRxiv.

[15]  K. Smalley,et al.  Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. , 2011, Biochemical pharmacology.

[16]  V. Sexl,et al.  c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard , 2011, Oncotarget.

[17]  Antoni Ribas,et al.  Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance , 2015, Cell.

[18]  Gary D. Bader,et al.  The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function , 2010, Nucleic Acids Res..

[19]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[20]  Dennis C. Friedrich,et al.  MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.

[21]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[22]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[23]  M. Gore,et al.  Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. , 2013, Cancer discovery.

[24]  Jason W. Locasale,et al.  Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. , 2017, Cell reports.

[25]  Xiaoyan Zhang,et al.  Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis , 2018, Nucleic Acids Res..

[26]  T. Gilmer,et al.  Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations , 2012, Molecular Cancer Therapeutics.

[27]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[28]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[29]  L. Garraway,et al.  C-RAF mutations confer resistance to RAF inhibitors. , 2013, Cancer research.

[30]  B. Taylor,et al.  A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor. , 2018, Cancer discovery.

[31]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[32]  L. Macconaill,et al.  Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. , 2017, Archives of pathology & laboratory medicine.

[33]  Hong Wang,et al.  A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. , 2017, Cancer research.

[34]  D. Polsky,et al.  Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. , 2003, Cancer research.

[35]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[36]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[37]  Howard Y. Chang,et al.  Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position , 2013, Nature Methods.

[38]  R. Johnson,et al.  c‐Jun regulates cell cycle progression and apoptosis by distinct mechanisms , 1999, The EMBO journal.

[39]  J. Larkin,et al.  Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. , 2015, Cancer cell.

[40]  Richard F. Kefford,et al.  Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. , 2012, The Journal of investigative dermatology.

[41]  Samantha E. Boyle,et al.  The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma , 2015, Science Signaling.

[42]  Myles Brown,et al.  Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute , 2019, Nature Protocols.

[43]  T. Graeber,et al.  JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma , 2016, Cell Discovery.

[44]  Shudong Wang,et al.  Targeting CDK6 in cancer: State of the art and new insights , 2015, Cell cycle.

[45]  Hanfei Sun,et al.  Target analysis by integration of transcriptome and ChIP-seq data with BETA , 2013, Nature Protocols.

[46]  Wei Xu,et al.  Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. , 2013, Cell reports.

[47]  Tero Aittokallio,et al.  SynergyFinder: a web application for analyzing drug combination dose–response matrix data , 2017, Bioinform..

[48]  T. Burke,et al.  The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation , 2013, Molecular Cancer Therapeutics.

[49]  A. Yoshida,et al.  Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. , 2016, Cancer research.

[50]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[51]  Jun S. Liu,et al.  Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR , 2015, Genome Biology.

[52]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[53]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[54]  Nicholas A. Sinnott-Armstrong,et al.  An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues , 2017, Nature Methods.

[55]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[56]  Paul S Mischel,et al.  Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032 , 2010, Journal of Translational Medicine.

[57]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[58]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[59]  R. Pearson,et al.  Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance , 2018, International journal of cancer.

[60]  Improved vectors and genome-wide libraries for CRISPR screening , 2014 .

[61]  Hong Wu,et al.  Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas , 2008, Molecular Cancer Therapeutics.

[62]  Clifford A. Meyer,et al.  Sequence determinants of improved CRISPR sgRNA design , 2015, Genome research.

[63]  E. Wagner,et al.  Control of cell cycle progression by c-Jun is p53 dependent. , 1999, Genes & development.

[64]  S. Nelson,et al.  Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.

[65]  M. Kot.  To cycle or not to cycle , 2001 .

[66]  V. Sondak,et al.  PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. , 2011, Cancer research.

[67]  Tao Liu,et al.  ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and analysis pipeline , 2016, BMC Bioinformatics.